Skip to main navigation Skip to search Skip to main content

REFRESH: A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension

Project: Research

Project Details

StatusActive
Effective start/end date09/9/21 → 06/30/26

Funding

  • Pharmaceutical Research Associates Incorporated: $84,928.49